RevenanasBook a free audit

Funding

Cloverleaf Bio raises USD 33M seed for engineered tRNA cancer therapeutics

September 8, 2026

Biotech

Funding

Key Facts

Signal Type

Funding

Industry

Biotech

Companies

Cloverleaf Bio, 4BIO Capital, AbbVie Ventures, Eli Lilly, Boehringer Ingelheim Venture Fund

Date

September 8, 2026

What Happened

Connecticut-based Cloverleaf Bio raised $33 million in an oversubscribed seed round to advance its engineered tRNA-based oncology platform. The round was led by 4BIO Capital and included strategic investments from AbbVie Ventures, Eli Lilly and Company, Boehringer Ingelheim Venture Fund, alongside Draper Associates, Mission BioCapital, and American Cancer Society BrightEdge.

Proceeds will support the lead inhibitory tRNA asset, CLB-001, toward early clinical testing in hepatocellular carcinoma (HCC), and preclinical development of an antibody-tRNA conjugate (ATC) targeting colorectal cancer. The company also previously received non-dilutive support through an NCI SBIR grant and a Lilly Genetic Medicine Grand Challenge award.

Who Is Affected

Cloverleaf Bio directly benefits from new capital to scale its team and move toward clinical trials. The company is a Yale University spinout founded by CEO Austin Draycott, CSO Cole Lewis, and SAB Chair Wendy Gilbert. Strategic pharma investors (AbbVie, Lilly, Boehringer) gain early access to a novel platform targeting RNA-modifying enzymes in oncology.

Vendors of clinical trial management software, CRO services, lab informatics, and preclinical research tools should consider this a new business opportunity as Cloverleaf expands operations to support IND-enabling studies.

Market Impact

The round signals continued investor appetite in tRNA-based therapeutics and RNA-modifying enzyme targets. The oversubscribed seed with three pharma strategic backers provides strong validation of the platform's potential beyond oncology (neurodegenerative and fibrotic diseases).

  • Strategic pharma involvement may accelerate partnership or licensing discussions, creating competitive pressure for similar platform companies.
  • Prior non-dilutive grants and the Lilly award demonstrate early independent validation, reducing risk for future investors.

What to Watch

Monitor Cloverleaf's progress toward IND-enabling studies for CLB-001 in HCC and whether the ATC program advances into animal models. Watch for further non-dilutive funding from NCI or expansion of the platform into non-oncology indications like neurodegeneration and fibrosis.

Also track hiring of clinical development and regulatory roles, a strong signal of imminent trial initiation. Any new strategic collaborations or follow-on funding from existing pharma backers would further validate the platform.

Related coverage

Source:

AllSci

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner